Novartis has agreed to buy exclusive worldwide rights to Abogen Biosciences’ lead mRNA-encoded CD19xCD3 T-cell engager, ABO2203, paying $575 million upfront in a deal that could total about $7.8 billion with development, regulatory and commercial milestones. The therapy is designed to be produced in vivo from the injected mRNA-lipid formulation, aiming to reset B cells through depletion for autoimmune disease. Abogen will also retain the ability to advance its RNA platform beyond the programs covered by the partnership, with the agreement including exclusive options to license additional next-generation assets. Novartis positions mRNA-encoded T-cell engagers as a way to complement existing modalities by enabling in vivo production rather than delivering recombinant proteins. The headline for biotech operators is how quickly large pharma is converting RNA platform validation into major licensing bets, with Abogen effectively trading early clinical risk for a potentially transformative scale-up pathway. For competitors, the deal underlines that CD19-targeted immune reset programs remain a key strategic lane in autoimmune. (Only the licensing/partnership items below were selected for this biotech-focused roundup.)